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Summary
Background: Platelets play a pivotal role in the
pathogenesis of acute coronary syndromes (ACS)
and their inhibition remains a mainstay therapy in
this setting. We aimed to perform a meta-analysis of
randomized trials to evaluate the benefits of new
oral antiplatelet regimens to block platelet ADP-
receptors compared to standard-dose clopidogrel
(300 mg loading dose followed by 75 mg/daily).
Methods: We obtained results from all randomized
trials enrolling patients with ACS. Primary endpoint
was mortality. Secondary endpoints were myocar-
dial infarction and definite in-stent thrombosis.
Safety endpoint was the risk of major bleeding com-
plications. We prespecified subanalyses according
to new antiplatelet drugs (prasugrel/ticagrelor),
high-dose clopidogrel (600 mg) and patients under-
going percutaneous coronary intervention.
Results: A total of seven randomized trials were
finally included in the meta-analysis (n = 58 591).
We observed a significant reduction in mortality
(2.9% vs. 3.4%, OR = 0.87, 95% CI 0.79–0.95,
P = 0.002), recurrent myocardial infarction (4.2%
vs. 5.2%, OR = 0.80, 95% CI 0.74–0.87,
P < 0.0001), definite in-stent thrombosis (0.9% vs.
1.7%, OR = 0.52, 95% CI 0.43–0.63, P < 0.0001).
The benefits in mortality and reinfarction were
driven by the treatment with prasugrel or ticagrelor,
without a significant difference in terms of major
bleeding complications as compared to standard-
dose clopidogrel (5% vs. 4.7%, OR = 1.06 95% CI
0.96–1.17, P = 0.25).
Conclusions: This meta-analysis showed that new
oral antiplatelet regimens are associated with a sig-
nificant reduction in mortality, reinfarction and
in-stent thrombosis in ACS patients without an over-
all increase of major bleeding when treated with
new antiplatelet drugs.
! The Author 2011. Published by Oxford University Press on behalf of the Association of Physicians.
All rights reserved. For Permissions, please email: journals.permissions@oup.com
Q J Med 2011; 104:561–569
doi:10.1093/qjmed/hcr069 Advance Access Publication 13 May 2011








Platelets play a pivotal role in the pathogenesis of
acute coronary syndromes (ACS). The combination
of aspirin and clopidogrel (300 mg loading dose
followed by 75 mg/daily) has represented for years
the oral antiplatelet therapy of choice.1 Large inter-
ests have been focused on new therapeutic strate-
gies to block ADP receptors in order to overcome
several limitations of clopidogrel, such as large
interindividual variability, delay in onset of action
and irreversibility.2–4 However, it must be recog-
nized that an improvement in platelet aggregation
inhibition may be counterbalanced by a higher
risk of bleeding complications.5 Thus, the aim of
the current study was to perform a meta-analysis
of randomized trials to evaluate the benefits in
terms of ischemic and bleeding complications of
new oral antiplatelet regimens to block platelet
ADP receptors as compared to standard dose of
clopidogrel.
Methods
Eligibility and search strategy
We obtained results from all randomized controlled
trials (RCTs) on adjunctive ADP receptor antagonists
among patients with ACS. The literature was
scanned by formal searches of electronic databases
(MEDLINE and CENTRAL) from January 1990 to
January 2010, the scientific session abstracts in
Circulation, Journal of the American College of
Cardiology, European Heart Journal and American
Journal of Cardiology from January 1990 to January
2011. Furthermore, oral presentations and/or expert
slide presentations were included (searched on the
TCT (www.tctmd.com), EuroPCR (www.europcr
.com), ACC (www.acc.org), AHA (www.aha.org)
and ESC (www.escardio.org) websites from January
2002 to January 2011. The following key words
were used: randomized trial, ACS, unstable
angina, coronary angiography, coronary angio-
plasty, antiplatelet therapy, thienopyridine, ADP an-
tagonist, clopidogrel, high-dose clopidogrel,
prasugrel, ticagrelor, AZD-6140. Inclusion criteria
were: (i) randomized treatment allocation and
(ii) availability of complete clinical data. Exclusion
criteria consisted of: (i) follow-up data in <90% of
the patients; (ii) ongoing studies or irretrievable data
and (iii) intravenous therapy with periprocedural but
not chronic administration. No language restrictions
were enforced.
Data extraction and validity assessment
Data were independently abstracted by two inves-
tigators. In case of incomplete or unclear data,
authors, where possible, were contacted.
Disagreements were resolved by consensus. Data
were managed according to the intention-to-treat
principle.
Outcome measures and prespecified
subanalyses
Clinical endpoints assessed were mortality as pri-
mary endpoint (all-cause mortality was preffered
when reported, or cardiovascular mortality), myo-
cardial infarction and definite in-stent thrombosis
(secondary endpoints) at follow-up, whereas major
bleeding complications (according TIMI major
bleeding definition when available, or according
to study definition) were assessed as safety endpoint.
We performed prespecified subanalyses accord-
ing to new antiplatelet drugs (prasugrel/ticagrelor),
high-dose clopidogrel (600 mg) and patients under-
going percutaneous coronary intervention (PCI).
Data analysis
Statistical analysis was performed using the Review
Manager 4.27 freeware package, SPSS 11.5 statistic-
al package. Odds ratio (OR) and 95% confidence
intervals (95% CIs) were used as summary statistics.
The pooled OR was calculated by using a fixed
effect model (the Mantel-Haenszel method) and
the random effect model between study heterogen-
eity was analyzed by means of I2 = [(Qdf)/Q]
100%, where Q is the 2 statistic, and df is its de-
grees of freedom. This describes the percentage of
the variability in effect estimates that is due to het-
erogeneity rather than sampling error (chance). A
value >50% may be considered substantial hetero-
geneity. The potential publication bias was exam-
ined by constructing a ‘funnel plot’, in which the
standard error (SE) of the ln OR was plotted against
the OR (mortality). Prespecified subanalyses were
conducted according to new antiplatelet drugs
(prasugrel/ticagrelor), high-dose clopidogrel and pa-
tients undergoing PCI. The study was performed in
compliance with the Quality of Reporting of
Meta-Analyses (QUOROM) guidelines.6
Results
A total of 10 RCTs were initially identified
(Figure 1).7–19 Two trials17,18 were excluded be-
cause of a temporary (periprocedural) intravenous
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ADP-blocker administration but not chronic ther-
apy. One trial was excluded because of comparison
between prasugrel and high-dose clopidogrel.19
Therefore, a total of seven randomized trials were
finally included in the meta-analysis (Table 1),
with 58 591 patients randomized to 300 mg clopi-
dogrel (n = 29 284) or new antiplatelet drugs
(prasugrel or ticagrelor) or dosages (high-dose clopi-
dogrel) (n = 29 307). A total of 43 807 patients
underwent PCI.
The TRITON-TIMI 387,8 included only patients
undergoing coronary angioplasty, with randomiza-
tion occurring just before the procedure. In the
PLATO trial,9,10 the decision to administrate a
bolus of 300 or 600 mg was left to the discretion
of local investigator. Finally, in the clopidogrel arm
59.5% of participants were treated with a loading
dose of 300 mg. In this study, 15 170 of 18 624 en-
rolled patients (81.4%) underwent coronary
angiography.
The DISPERSE-2 study16 was a second phase clin-
ical trial in which patients were randomly assigned
in a 1:1:1 double-blind fashion to receive either
twice daily ticagrelor 90 mg, ticagrelor 180 mg or
clopidogrel 300 mg loading dose plus 75 mg once
daily for up to 12 weeks. In our meta-analysis, we
included only patients receiving the dose of ticagre-
lor used in the PLATO trial.
In the CURRENT OASIS-7 trial,14 patients referred
to invasive management were assigned to high-dose
clopidogrel [600 mg bolus and a daily double dose
of clopidogrel (150 mg) up to 7 days after enrolment]
or to a standard clopidogrel regimen. In this trial,
patients were additionally randomized to low
(75–100 mg) or high-dose (300–325 mg) aspirin. In
the ALBION trial,11 patients were randomized to
300, 600 and 900 mg clopidogrel.
Primary endpoint
Follow-up data were collected at 30 days or up to
12–15 months (PLATO and TRITON-TIMI 38)7–10
follow-up. A total of 1886 patients died (3.2%).
We observed a significant reduction in mortality
with new regimens (2.9% vs. 3.4%, OR = 0.87,
95% CI 0.79–0.95, P = 0.002, Pheter = 0.32)
(Figure 2: total), that was confined to new molecules
(3.6% vs. 4.3%, OR = 0.83, 95% CI 0.74–0.92,
P = 0.0002, Pheter = 0.21), especially to ticagrelor,
as observed in the PLATO trial (Figure 2A: novel
antiplatelet drugs). Similar results were observed in
patients undergoing PCI (n = 43 807) (2.4% vs.
2.7%, OR = 0.88 (95% CI 0.78–0.99, P = 0.03,
Pheter = 0.13) (Figure 2B: PCI subgroup). As shown
in Figure 3, no publication bias was observed.
Secondary endpoints
Myocardial infarction
Follow-up data were collected at 30 days or up to
12–15 months (PLATO and TRITON-TIMI 38)7–10
follow-up. Recurrent myocardial infarction was
observed in 2740 (4.7%) patients. A significant re-
duction was observed with new regimens as com-
pared to standard-dose clopidogrel (4.2% vs. 5.2%,
OR = 0.80, 95% CI 0.74–0.87, P < 0.0001,
Pheter = 0.15) (Figure 4: total). The benefits were
mostly evident with new agents (6.0% vs. 7.5%,
OR = 0.79, 95% CI 0.72–0.86, P < 0.0001,
Pheter = 0.11) (Figure 4A: novel antiplatelet drugs)
but not with high-dose clopidogrel (2% vs. 2.2%,
OR = 0.88, 95% CI 0.75–1.05, P = 0.16,
Pheter = 0.3) (Figure 4B: 600 mg clopidogrel).
Similar benefits were observed when restricted to
patients undergoing coronary angioplasty (4.5% vs.
6%, OR = 0.73, 95% CI 0.67–0.80, P < 0.0001,
Pheter = 0.24) (Figure 4C: PCI subgroup).
In-stent thrombosis
Follow-up data were collected at 30 days or up to
12–15 months (PLATO and TRITON-TIMI 38)7–10
follow-up. Definite in-stent thrombosis was
observed in a total of 517 out of 40 276 patients
(1.3%). Therapy with ADP-antagonist regimens
when compared to standard-dose clopidogrel was
associated with a significant reduction in definite
in-stent thrombosis (0.9% vs. 1.7%, OR = 0.52,
95% CI 0.43–0.63, P < 0.0001, Pheter = 0.40)
(Figure 5).
Safety endpoint
A total of 1973 patients (3.4%) had a major bleeding
complication. High-dose (600 mg) clopidogrel as
compared with 300 mg clopidogrel was associated
Figure 1. Flow diagram of the systematic overview
process.
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with a higher rate of major bleedings (1.6% vs.
1.3%, OR = 1.25, 95% CI 1.02–1.53, P = 0.03,
Pheter = 0.45) (Figure 6B: 600 mg clopidogrel).
Conversely, as compared with standard dose of
clopidogrel, the new drugs did not significantly in-
crease the rate of major bleeding complications (5%
vs. 4.7%, OR = 1.06, 95% CI 0.96–1.17, P = 0.25,
Pheter = 0.10) with the lower rates of bleedings
confined to ticagrelor (Figure 6A: novel antiplatelet
drugs). These results did not differ when the analysis
was restricted to patients undergoing coronary inter-
vention (Figure 6C: PCI subgroup).
Discussion
New antiplatelet regimens are regarded as major
advance in cardiovascular therapy. The results of
our meta-analysis of seven RCTs,7–16 including
58 591 patients with ACS, showed that, when com-
pared with standard-dose clopidogrel (300 mg load-
ing dose), new antiplatelet regimens are associated
with a significant reduction in mortality, reinfarction
and in-stent thrombosis.
High-dose clopidogrel significantly increased the
risk of major bleeding complications; an increased
number of major bleedings was also observed with
prasugrel, even though the overall subgroup of new
antiplatelet drugs (prasugrel and ticagrelor) was not
associated with an increased rate of major
bleedings.
In terms of clinical efficacy and safety, the overall
benefits were more pronounced with the new anti-
platelet compound ticagrelor. The same clinical
benefits observed in the overall analysis were con-
sistent in the prespecified subgroup of patients
Figure 2. All-cause mortality in the overall population with ORs and 95% CI. (A–C) Prespecified subanalysis for mortality in
the group of novel antitplatet drugs (A), 600 mg of clopidogrel (B) and PCI subgroup (C); ORs and 95% CI are reported.
The size of the data markers (squares) is approximately proportional to the statistical weight of each trial; *= cardiovascular
mortality.
Figure 3. Funnel plot for mortality of the studies included
in the meta-analysis. The SE of the ln OR was plotted
against the OR for mortality. No skewed distribution was
observed, suggesting no publication bias. ALBION study
was not included in the graph because there was no
computed effect size due to absence of events in the
two arms (novel antiplatelet regimens vs. standard-dose
clopidogrel).
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undergoing PCI, where all the treatments did not
increase the risk of major bleeding complications.
Standard-dose clopidogrel (300 mg bolus fol-
lowed by 75 mg/daily) has been regarded for years
as the gold standard of adjunctive antiplatelet
therapy in patients with ACS treated with or without
an interventional strategy.1 Several limitations of
clopidogrel2–4 have raised the need for new thera-
pies. First of all, many patients still have events des-
pite dual antiplatelet therapy. Several factors may
Figure 4. Recurrent myocardial infarction in the overall population, with ORs and 95% CI. (A–C) Prespecified subanalysis
for myocardial infarction in the group of novel antitplatet drugs (A), 600 mg of clopidogrel (B) and PCI subgroup (C); ORs and
95% CI are reported. The size of the data markers (squares) is approximately proportional to the statistical weight of each
trial.
Figure 5. In-stent thrombosis in the overall population with ORs and 95% CI. The size of the data markers (squares) is
approximately proportional to the statistical weight of each trial.
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contribute to clinical resistance to clopidogrel.20
Due to its complex metabolic pathway, clopidogrel
takes 4 h to reach peak platelet aggregation inhib-
ition. Since many patients take clopidogrel loading
dose just before PCI, they are at risk of ischemic
periprocedural events. Furthermore, due to poly-
morphisms of several enzymes involved in the mul-
tistep metabolic pathway of clopidogrel, a large
interindividual variability in platelet aggregation in-
hibition has been observed, with prevalence of re-
sistance to clopidogrel ranging from 15% to 30%.
Moreover, clopidogrel has irreversible effects that in
some cases prevent from early administration before
the procedure, especially in the setting of ACS
where a relatively large proportion of patients (10–
30%) has severe multivessel disease requiring
bypass surgery, whereas a drug with reversible ef-
fects may overcome this limitation and increase the
administration of early antiplatelet therapy.
However, a faster and stronger antiplatelet ther-
apy may be associated with higher risk of bleeding
complications that may counterbalance the benefits
in terms of thrombotic complications.5
Several new therapeutic strategies have been
proposed to overcome some limitations of
standard-dose clopidogrel. High-dose clopidogrel
has been shown to provide a faster and stronger in-
hibition of platelet aggregation with a lower percent-
age of resistance.
The CURRENT OASIS-7 trial showed that
high-dose clopidogrel was associated with a slightly
higher risk of bleeding complications [TIMI major
bleedings: 210 (1.7%) vs. 168 (1.3%), P = 0.03] but
benefits in reinfarction [237 (1.9%) vs. 277 (2.2%),
P = 0.09], mainly due to a significant reduction of
in-stent thrombosis [definite in-stent thrombosis 58
(0.7%) vs. 111 (1.3%); P = 0.0001).14,15
Prasugrel is a third-generation thienopyridine with
a rapid and effective metabolic activation that is
associated with a faster onset of action and an
increased inhibition of platelet aggregation when
compared to clopidogrel. Data from the
TRITON-TIMI 38 showed significant benefits in
terms of myocardial infarction and significant reduc-
tion in in-stent thrombosis.7,8 Even though it was
counterbalanced by a higher risk of major bleeding
complications, the benefits in terms of thrombotic
complications largely outweighed bleeding compli-
cations. Low body weight (460 kg), advanced age
(>75 years) and previous stroke were predictors of
Figure 6. Major bleeding complications in the overall population with ORs and 95% CI. (A–C) Prespecified subanalysis for
major bleedings in the group of novel antitplatet drugs (A), 600 mg of clopidogrel (B) and PCI subgroup (C); the size of the
data markers (squares) is approximately proportional to the statistical weight of each trial.
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higher risk of bleeding complications, and in such
patients the drug should not be administrated.
However, a new ongoing trial, the TRILOGY trial,
is investigating the benefits from a lower (half)
dosage (30 mg bolus and 5 mg daily) in patients
with ACS undergoing conservative therapy. In fact,
one of the limitations of the TRITON-TIMI 38 trial
was the enrolment of patients after initial angiog-
raphy, but not at the very beginning of presentation
of ACS (hospital admission).
Ticagrelor is a non-thienopyridine with a faster
onset and offset of action and significantly higher
inhibition of platelet aggregation as compared to
600 mg clopidogrel. One of the great advantages
that make the molecule very appealing is the revers-
ibility of its antiplatelet effect, with the drug admini-
strated twice a day. This is extremely important,
when the overall ACS population is taken into ac-
count. In fact, a considerable proportion of patients,
ranging from 20% to 30%, undergo coronary artery
bypass grafting (CABG) during hospitalization,
where the risk of bleeding may become very high.
Data from the large PLATO trial9,10 showed a sig-
nificant reduction in mortality, in addition to bene-
fits in myocardial infarction and in-stent thrombosis.
No difference was observed in terms of major bleed-
ing complications. However, paradoxically, while a
lower incidence of bleeding was observed in pa-
tients undergoing CABG, in non-CABG patients tica-
grelor was associated with a significantly higher rate
of major bleeding complications.
Our meta-analysis showed in 58 591 ACS patients
that new oral antiplatelet therapies are associated
with a significant reduction in mortality, recurrent
myocardial infarction, especially with new drugs
(prasugrel/ticagrelor). The benefits in mortality
were mostly observed with ticagrelor, whereas the
benefits regarding in-stent thrombosis were consist-
ent with all the strategies. A higher risk of major
bleeding complications was observed with both
high-dose clopidogrel and prasugrel that dis-
appeared in the analysis restricted to patients under-
going coronary angioplasty.
Limitations
This meta-analysis was not performed on individual
patient’s data that would have certainly improved
the results, particularly by performing subgroup ana-
lyses. Furthermore, the trials included in our
meta-analysis tested three different regimens (prasu-
grel, ticagrelor and high-dose clopidogrel) against
standard-dose clopidogrel.
Conclusions
This meta-analysis of randomized trials conducted
in ACS patients showed that new oral antiplatelet
regimens to block platelet ADP-receptor are asso-
ciated with a significant reduction in mortality, rein-
farction, especially with ticagrelor and prasugrel. A
higher risk of major bleeding complications was
observed with both prasugrel and high-dose clopi-
dogrel, that disappeared in the analysis restricted to
patients undergoing coronary angioplasty, where
clear and consistent benefits in terms of in-stent
thrombosis were observed with all the new therapies
as compared to standard-dose clopidogrel.
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